| 1.37 -0.01 (-0.72%) | 10-19 11:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.78 | 1-year : | 1.92 |
| Resists | First : | 1.52 | Second : | 1.64 |
| Pivot price | 1.44  |
|||
| Supports | First : | 1.33 | Second : | 1.1 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.46 |
| MA(100) : | 1.49 |
MA(250) : | 2.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 19.7  |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 13.25 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ENVB ] has closed above bottom band by 7.7%. Bollinger Bands are 51.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 81 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.39 | 1.39 - 1.4 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.36 - 1.38 | 1.38 - 1.39 |
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Wed, 14 Oct 2026
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits
Fri, 14 Aug 2026
Armistice Capital (ENVB) discloses 405,092-share position in Enveric Biosciences - Stock Titan
Thu, 23 Jul 2026
Enveric Biosciences (ENVB) Retreats 4.5% as Selling Pressure Intensifies Near Key Support - PCR Spike - www.dars.gov.et
Tue, 28 Apr 2026
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors - Investing News Network
Fri, 24 Apr 2026
What's Going On With Enveric Biosciences Stock On Friday? - Benzinga
Mon, 20 Apr 2026
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 12 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | -13.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.4 % |
| Return on Equity (ttm) | -170.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|